Medigene's Drug Veregen® receives market approval in the Czech Republic
(Thomson Reuters ONE) -
Medigene AG /
Medigene's Drug Veregen® receives market approval in the Czech Republic
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Martinsried/Munich, March 15, 2013. Medigene AG (MDG, Frankfurt, Prime Standard)
announces that its drug Veregen(®) has obtained market approval in the Czech
Republic. Medigene's marketing partner Nordic Pharma is planning to launch
Veregen(®) in the Czech Republic, Poland, Hungary, and Slovakia during 2013,
upon conclusion of the reimbursable price-fixing procedure by the responsible
authority.
Veregen(®) is already being marketed in the USA, Germany, Switzerland, Austria,
and Spain by the sales partners Fougera, Abbott, and Bial. Market approvals and
the launch in additional countries are pending in 2013. Medigene has entered
into several marketing partnerships for Veregen(®) across Europe, Asia, and
America, and is planning to continue this global licensing strategy to further
exploit the product's market potential.
About Veregen(®): Veregen(®), an ointment used in the topical treatment of
external genital warts, contains a catechin concentrate based on a defined
extract obtained from green tea leaves. Since 2010, Veregen(®) (Sinecatechins
15% ointment) has been recommended in the US Department of Health and Human
Services Center for Disease Control and Prevention's Sexually Transmitted
Diseases Treatment Guidelines as a possible option for treating genital warts.
Sinecatechins 10% & 15% ointment (Veregen(®)) was recently also included in the
European Guideline for the Management of Anogenital Warts.
Medigene AG (Frankfurt: MDG, prime standard) is a publicly listed biotechnology
company headquartered in Martinsried/Munich, Germany. Medigene focuses on
clinical research and development of novel drugs against cancer and autoimmune
diseases. Medigene was the first German biotech company to have revenues from
marketed products, which are distributed by partner companies. It has two drug
candidates in clinical trials, EndoTAG(®)-1 and RhuDex(®), and is developing an
innovative vaccine technology. For more information, please visit
www.medigene.com.
This press release contains forward-looking statements representing the opinion
of Medigene as of the date of this release. The actual results achieved by
Medigene may differ significantly from the forward-looking statements made
herein. Medigene is not bound to update any of these forward-looking statements.
Medigene(®) and Veregen(®) are registered trademarks of Medigene AG. Polyphenon
E(®) is a trademark of Mitsui Norin Co., Ltd. These trademarks may be owned or
licensed in select locations only.
Kontakt
Julia Hofmann, Claudia Burmester
Investor & Public Relations
Tel.: +49 - 89 - 20 00 33 - 33 01
Email: investor(at)medigene.com
To unsubscribe from the press release distribution list, please go to
www.medigene.com/unsubscribe.
Press Release as PDF:
http://hugin.info/132073/R/1685435/552149.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Medigene AG via Thomson Reuters ONE
[HUG#1685435]
Unternehmensinformation / Kurzprofil:
Datum: 15.03.2013 - 07:30 Uhr
Sprache: Deutsch
News-ID 239737
Anzahl Zeichen: 4000
contact information:
Town:
Martinsried / München
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 161 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Medigene's Drug Veregen® receives market approval in the Czech Republic"
steht unter der journalistisch-redaktionellen Verantwortung von
Medigene AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
